Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: Evidence for enhancement of potency

Biochemical Pharmacology

Volumn 70, Issue 4, 2005, Pages 511-519

  Brahimi, Fouad ^a   Rachid, Zakaria ^a   McNamee, James P ^b   Alaoui Jamali, Moulay A ^c   Tari, Ana M ^d   Jean Claude, Bertrand J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b HEALTH CANADA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; DNA damage; EGFR signaling; In vivo efficacy; O6 alkylguanine transferase; Quinazolines

Indexed keywords

ALKYLATING AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; FD 105; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; QUINAZOLINE DERIVATIVE; SMA 41; UNCLASSIFIED DRUG; ZRBA 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DRUG DESIGN; DRUG EFFECT; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG POTENCY; DRUG SOLUBILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

APOPTOSIS; CELL LINE, TUMOR; COMET ASSAY; DNA DAMAGE; HUMANS; HYDROLYSIS; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SOLUBILITY; TRIAZENES;

EID: 22144443208     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.04.037     Document Type: Article

References (23)

1. P.G. Koenders, L.V. Beex, A. Guerts-Moespat, J.J. Heuvel, C.B. Kienhuis, and T.J. Benraad Epidermal growth factor receptor-negative tumours are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers Cancer Res 51 1991 4544 4548
2. D.J. Slamon, W. Godolphin, and L.A. Jones Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
3. S.L. Matheson, J.P. McNamee, and B.J. Jean-Claude Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumour targeting strategy J Pharm Exp Ther 296 2001 832 840
4. F. Brahimi, S.L. Matheson, J.P. McNamee, A. Tari, and B.J. Jean-Claude Inhibition of epidermal growth factor receptor-mediated signaling by "combi-triazene" BJ2000, a new probe for the Combi-Targeting postulates J Pharm Exp Ther 303 2002 238 246
5. Q. Qiu, F. Dudouit, S.L. Matheson, F. Brahimi, R. Banerjee, and J.P. Mcnamee The combi-targeting concept: a novel 3,3-disubstitued nitrosourea with EGFR tyrosine kinase inhibitory properties Cancer Chemother Pharmacol 51 2003 1 10
6. S.L. Matheson, J.P. McNamee, and B.J. Jean-Claude Differential responses of EGFRE/AGT-expressing cells to the "combi-tirazene" SMA41 Cancer Chemother Pharmacol 51 2003 11 20
7. Z. Rachid, F. Brahimi, N. Teoh, A. Katsoulas, and B.J. Jean-Claude Chemical dissection of the binary properties of a series of combi-triazenes J Med Chem 46 2003 4313 4321
8. S.L. Matheson, J.P. McNamee, T. Wang, M.A. Alaoui-Jamali, and B.J. Jean-Claude The combi-targeting concept: dissection of the binary mechanism of action of the combi-tiazene SMA41 in vitro and antitumour activity in vivo J Pharm Exp Ther 311 2004 1163 1170
9. A.J. Fornace Jr., M.A. Papathanasiou, M.C. Hollander, and D.B. Yarosh Expression of the O6-methylguanine-DNA methyltransferase gene MGMT in MER+ and MER- human tumor cells Cancer Res 50 1990 7908 7911
10. J.B. Smaill, G.W. Rewcastle, J.A. Loo, K.D. Greis, O.H. Chan, and E.L. Reyner Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3, 2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions J Med Chem 43 2000 1380 1397
11. H.W. Manning, L.M. Cameron, R.J. LaFrance, K. Vaughan, and R. Rajaman Triazene metabolism. V. Chemical and biological properties of N,N-bis-[1-aryl-3-methyltriazen-3-yl)-methyl]-methylamines: potential prodrugs for the cytotoxic monomethyltriazenes Anti-Cancer Drug Des 1 1985 37 43
12. G.W. Rewcastle, W.A. Denny, A.J. Bridges, H. Zhou, D.R. Cody, and A. McMichael Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor J Med Chem 38 1995 3482 3487
13. D.W. Fry, A.J. Bridges, W.A. Denny, A. Doherty, K.D. Greis, and J.L. Hicks Specific irreversible inactivation of the epidermal growth factor receptor and ErbB2, by a new class of tyrosine kinase inhibitor Proc Natl Acad Sci 95 1998 12022 12027
14. A.M. Tari, and G. Lopez-Berestein Serum predominantly activates MAPK and Akt kinases in EGFR- and ErbB2-overexpressing cells, respectively Int J Cancer 86 2000 295 297
15. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, and D. Vistica New colorimetric cytotoxicity assay for anti-cancer drug screening J Natl Cancer Inst 82 1990 1107 1112
16. J.P. McNamee, J.R. Mclean, C.L. Ferrarotto, and P.V. Bellier Comet assay: rapid processing of multiple samples Mutat. Res 466 2000 63 69
17. Merayo N, Rachid Z, Brahimi F, Jean-Claude BJ. The combi-targeting concept: evidence for the formation of new metabolites. Cancer Lett, submitted for publication.
18. R.J. Davis The mitogen-activated protein kinase signal transduction pathway J Biol Chem 268 1993 14553 14556
19. M.A. Olayioye, R.M. Neve, H.A. Lane, and N.E. Hynes The ErbB signaling network: receptor heterodimerization in development and cancer EMBO J 19 2000 3159 3167
20. H. Modjtahedi, S. Eccles, G. Box, J. Styles, and C. Dean Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction Br J Cancer 67 1993 254 261
21. S.Y. Park, and D.W. Seol Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis Biochem Biophys Res Commun 295 2002 515 518
22. S. Huang, E.A. Armstrong, S. Benavente, P. Chinnaiyan, and P.M. Harari Dual-agent molecular targeting of the epidermal growth factor recptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor Cancer Res 64 2004 5355 5362
23. Matheson SL, Brahimi F., Jean-Claude BJ. The combi-tarteting concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41. Biochem Pharmacol 2004;67:1131-38.